PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT04832139
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
- Conditions
- Transthyretin Amyloid Polyneuropathy (ATTR-PN)
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04828993
- Locations
- 🇨🇳
Peking union hospital of Chinese academy of medical sciences, Beijing, China
🇨🇳Tiantan Hospital Capital Medical University, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Monitoring Activity And Gait In Children
- Conditions
- Child, PreschoolAdolescentChild
- Interventions
- Device: Panoramic Bracelet and GENEActiv
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT04823650
- Locations
- 🇺🇸
Pfizer Innovation Research, PfIRe, Lab, Cambridge, Massachusetts, United States
A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 599
- Registration Number
- NCT04822350
- Locations
- 🇫🇷
Centre Hospitalier Victor Dupouy, Argenteuil Cedex, France
🇫🇷CHU Amiens-Picardie, Amiens Cedex 1, France
🇫🇷Centre Hospitalier de la cote Basque, Bayonne, France
Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years
- Conditions
- Esophagitis
- Interventions
- Drug: Full dose Pantoprazole plus matching placeboDrug: Half Dose Pantoprazole plus matching placebo
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT04821310
- Locations
- 🇬🇪
JSC Georgian Clinics, Tbilisi, Georgia
🇮🇳Medical college and Hospital, Kolkata, WEST Bengal, India
🇸🇰CLINIQ s.r.o., Bratislava, Slovakia
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 599
- Registration Number
- NCT04821622
- Locations
- 🇺🇸
Kelsey Research Foundation, Houston, Texas, United States
🇺🇸Urology San Antonio, PA dba USA Clinical Trials, San Antonio, Texas, United States
🇺🇸Urology San Antonio, San Antonio, Texas, United States
Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
- Conditions
- Meningococcal Vaccine
- Interventions
- Biological: Nimenrix
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT04819113
- Locations
- 🇵🇱
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow, Poland
🇫🇮Tampere Vaccine Research Clinic, Tampere, Pirkanmaa, Finland
🇫🇮Jarvenpaa Vaccine Research Center, Jarvenpaa, Finland
Drug Use Investigation of COMIRNATY Intramuscular Injection
- Conditions
- COVID-19
- Interventions
- Biological: BNT162b2
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14570
- Registration Number
- NCT04815031
- Locations
- 🇯🇵
PfizerLocal Country Office, Tokyo, Japan
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04814186
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
NOAC Portuguese Real World Study
- Conditions
- StrokeSystemic EmbolismMajor Bleeding
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04808934